News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Calithera Biosciences, Inc. (CALA) Reports Fourth Quarter And Full Year 2014 Financial Results And Recent Highlights 3/27/2015
New Research Throws Cold Water on Biogen (BIIB)'s Recent Breakthrough 3/26/2015
Aridis Pharmaceuticals Commences Phase 1 Clinical Study Of Aerucin Monoclonal Antibody For Acute Pneumonia 3/26/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results From Phase 1 AME & Renal Clearance Clinical Studies Of Neuropsychiatric Drug Candidate ELND005 3/26/2015
Essentialis Presents Results From The First Phase Of Clinical Study PC025 Evaluating DCCR In The Treatment Of Prader-Willi Syndrome At ACMG Annual Clinical Genetic Meeting 3/26/2015
Immune Design Corporation (IMDZ) Announces Treatment Of Patients With CMB305 Investigational Immuno-Oncology Agent 3/26/2015
Tianjin CanSino Biotechnology Release: China Ebola Vaccine Passes Phase I Test 3/26/2015
Zogenix (ZGNX) Announces First Patient Dosed In Relday Multi-Dose Clinical Study 3/26/2015
Vical Incorporated (VICL) Expands Infectious Disease Portfolio With Novel Antifungal From Astellas Pharma Inc. (ALPMY) 3/26/2015
MorphoSys AG And Celgene (CELG) Mutually Agree To End MOR202 Collaboration 3/26/2015
Aduro Biotech Receives Orphan Drug Designation For CRS-207 In Mesothelioma 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Biogen (BIIB) Alzheimer's Drug Aducanumab Exceeds Expectations 3/25/2015
Regulus Therapeutics, Inc. (RGLS) Receives Orphan Medicinal Product Designation From The European Commission (EC) For RG-012, A Microrna Therapeutic In Development For The Treatment Of Alport Syndrome 3/25/2015
Cellular Biomedicine Group (CBMG) Announces Phase I Results From CAR-T Immuno-Oncology Clinical Development Programs 3/25/2015
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302 3/25/2015
BioLineRx Ltd. Reports Successful Top-Line Safety And Efficacy Results For Novel Stem Cell Mobilization Treatment 3/25/2015
Tenth Cohort Completed In Cellceutix (CTIX) Clinical Trial Of Anti-Cancer Drug Kevetrin, No Adverse Events Reported 3/25/2015
Biogen (Cambridge, MA) Drops Idec From Corporate Name, Expands Ambitions in Alzheimer's, ALS 3/24/2015
Prothena (PRTA) Soars on Positive Phase I Results Of Parkinson's Drug PRX002 3/24/2015
Relmada Therapeutics Receives Health Canada Clearance To Commence First Clinical Study For Novel Oral Formulations Of Buprenorphine 3/24/2015
GenVec Inc. (GNVC) Reports Fourth Quarter And 2014 Year-End Financial Results 3/24/2015
Eli Lilly (LLY),Novartis AG (NVS)-Backed Startup, Aeglea, Nabs $44 Million 3/23/2015
Another Day, Another $456 Million Cancer Pact for Eli Lilly (LLY) 3/23/2015
Biogen (BIIB) Slides For Alzheimer's Drug Wow Analysts, Set Up Fight for Eli Lilly (LLY) 3/23/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 1 Data on Isis-ANGPTL3Rx 3/23/2015
GenVec Inc. (GNVC) And TheraBiologics Form Collaboration To Develop Neural Stem Cell Mediated Cancer Therapies 3/23/2015
AB Science (AB.PA): Masitinib Receives Orphan Drug Designation For Amyotrophic Lateral Sclerosis From FDA 3/23/2015
Kamada Ltd. (KMDA) Awarded European Orphan Drug Designation For Its Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease 3/23/2015
Alzheon Announces Phase 1 Results Of ALZ-801, A First-in-Class Inhibitor Of Amyloid Formation And Neurotoxicity For Alzheimer’s Disease 3/20/2015
Biogen Idec (BIIB) Presents Positive Interim Results From Phase 1B Study Of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) At 2015 AD/PD Conference 3/20/2015
Synthetic Biologics, Inc. (SYN) Announces Positive Pharmacokinetics Data From Phase 1a And 1b Trials Of SYN-004 To Protect The Microbiome And Prevent C. difficile Infection 3/19/2015
HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan 3/19/2015
Advaxis, Inc. Announces First Patient Treated In Phase 1/2 Dose-Escalation Study Of ADXS-HPV For Recurrent Cervical Cancer 3/19/2015
John Theurer Cancer Center Joins Study Exploring Novel Delivery Of Cancer-Selective Gene Therapy To Treat Brain Cancer 3/19/2015
Neurotensin, Vectorised By Vect-Horus, Is The First Drug-Candidate In Neuroprotective Hypothermia 3/19/2015
Heron Therapeutics, Inc. (APPA) Reports Positive Results From Phase 1 Study Of HTX-011 3/19/2015
Eli Lilly (LLY), Hanmi Pharma Forge $690 Million Autoimmune Pact 3/19/2015
Expectations are High as Biogen Idec (BIIB) Prepares to Reveal Alzheimer's Data 3/18/2015
Lixte Biotechnology Completes Private Placement Of Convertible Preferred Stock 3/18/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review 3/17/2015
Relmada Therapeutics Reports Positive Phase 1 Results For NMDA Receptor Antagonist D-Methadone 3/17/2015
Zai Lab Begins Trial Of Novel Respiratory Disease Drug 3/17/2015
GliaCure Receives $1 Million Grant For Phase 1b Alzheimer's Clinical Trial 3/17/2015
Advaxis, Inc. Presents Preliminary Data From A Phase I/II Trial Of ADXS-HPV In HPV-Associated Anal Cancer In Combination With Chemoradiation Showing Complete Response And No Recurrences To Date In All Treated Patientsa 3/16/2015
PharmaCyte Biotech (NVLX) Provides Update On Corporate Developments And Progress With Cancer And Diabetes Programs 3/16/2015
VAXIL Receives EU Orphan Drug Designation For Immucin For The Treatment Of Multiple Myeloma 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
NeuralStem Inc. Reports Fiscal 2014 Fourth Quarter Financial And Year-End Business Results 3/16/2015
Cleveland Biolabs Inc. (CBLI) Announces Completion Of Dosing In Phase I Study Of CBLB612 In Russian Federation 3/16/2015
ASLAN Reports Positive Phase I Results From Cancer Drug 3/16/2015
Rock Creek Pharmaceuticals Files 2014 Annual Report And Provides Clinical Development Update 3/13/2015
Dr. Falk Pharma And Zedira Enter Phase I Clinical Trials For A Celiac Disease Drug 3/13/2015
Annias Immunotherapeutics, Inc. Release: Dramatic Patient Survival Benefit Shown For New Approach To Treating Glioblastoma Multiforme Licensed To Annias Immunotherapeutics 3/12/2015
TiGenix Completes Treatment In Phase I Sepsis Challenge Trial With Cx611 3/12/2015
Protalex, Inc. (PRTX) Initiates Enrollment Of Phase I/II Continuation Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 3/12/2015
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of Its Novel Anemia Therapeutic TBI 304H 3/12/2015
Concert Pharmaceuticals, Inc. (CNCE) Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor For Cystic Fibrosis 3/12/2015
Lpath, Inc. (LPTN) To Submit Additional Data For Lpathomab Investigational New Drug Application 3/11/2015
Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial 3/11/2015
Soligenix (SNGX) Announces Publication Of Successful Preclinical Efficacy And Immunogenicity Results For Ricin Toxin Vaccine 3/11/2015
Dr. Anita J. Chawla Joins CytRx Corporation (CYTR) Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology 3/11/2015
Antibe Therapeutics Inc. (ATE.V) Provides An Update On Its Data Review And Corporate Strategy 3/11/2015
MorEx Moves To Intent-to-Cure Stage Of MTL-005 Radiation Enhancer Head & Neck Cancer Phase 1 Trial 3/11/2015
PacificGMP And ArmaGen Technologies, Inc. Announce Successful Manufacture Of Armagen's Investigational Enzyme Replacement Therapies, AGT-182 And AGT-181, For Phase 1 Clinical Trial 3/10/2015
Halozyme Therapeutics, Inc. (HALO) Reports Selection Of First Product Candidate Under Janssen Biotech Inc. (JNJ) Collaboration 3/10/2015
Innate Pharma (IPH.PA ) Collaborates With NCIC Clinical Trials Group On The Phase I/II Trial Of IPH2201 In Ovarian Cancer 3/9/2015
Emergent BioSolutions (EBS) And MorphoSys AG Initiate Phase 1 Clinical Study To Evaluate The Novel Oncology Immunotherapeutic MOR209/ES414 For Prostate Cancer 3/9/2015
Heat Biologics Receives U.S. FDA Fast Track Designation For HS-410 (Vesigenurtacel L) In Combination With BCG For The Treatment Of Non-Muscle Invasive Bladder Cancer 3/9/2015
Versartis, Inc. (VSAR) Presents 12-Month Data For VRS-317 At Late-Breaker Session At Endocrine Society's Annual Meeting 3/9/2015
ORYX Successfully Completes Phase 1/2a Trial With Therapeutic Vaccine Vicoryx To Treat HPV-Associated Cancers 3/9/2015
Targovax To Expand On-Going Phase I/II CT-TG01-01 Pancreatic Cancer Study With A New Group Of Up To 13 Patients 3/9/2015
XOMA (US) LLC (XOMA) Presents Positive Phase I XOMA 358 Data At The ENDO Meeting 3/9/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
XOMA (US) LLC (XOMA) Will Present XOMA 358 Phase 1 Data At ENDO 2015 3/6/2015
EXCLUSIVE: Experimental Cancer Drug From Oncoceutics Could Be Fast-Tracked, Says Exec 3/6/2015
Asterias Biotherapeutics Initiates Patient Enrollment For Phase 1/2a Clinical Trial Of AST-OPC1 In Newly Injured People With Complete Cervical Spinal Cord Injury 3/5/2015
Ironwood Pharmaceuticals (IRWD) Initiates Phase I Clinical Study Of sGC Stimulator IW-1973 3/5/2015
Molecular Templates Inc. Announces Start Of Phase 1 Clinical Trial Of MT-3724 In Refractory Non-Hodgkin’s Lymphoma 3/5/2015
Eisai Company, Ltd. (ESALY.PK) And Merck & Co. (MRK) Enter Collaboration To Explore Novel Combination Regimens Of Anti-PD-1 Therapy With Multi-Targeting RTK Inhibitor And Microtubule Dynamics Inhibitor In Multiple Types Of Cancer 3/5/2015
Symbiomix Therapeutics, LLC Studies Show Drug Candidate For Women's Health Infections Is Safe And Well-Tolerated 3/4/2015
Immunomic Therapeutics Explains Proprietary LAMP-vax Platform In Nature Advertorial Supplement 3/4/2015
Aerpio Announces Publication Of Positive Results Of Phase 1b/2a Clinical Trial Of Novel Tie2 Activator, AKB-9778, For The Treatment Of Patients With Diabetic Macular Edema (DME) – TIME-1 Study 3/4/2015
Clinical Study Published In Neurology Finds That electroCore’s Non-Invasive Vagus Nerve Stimulation Is Effective In Treating Cluster Headaches 3/3/2015
Rutgers Cancer Institute Of New Jersey Starts ONC201 Clinical Trials 3/3/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Primary Peritoneal Cancer 3/3/2015
Adamis Pharmaceuticals (ADMP) Announces Positive Pharmacokinetic Study Results For Its Dry Powder Inhaler Product 3/3/2015
Pulmokine Receives $1 Million Investment From Broadview Ventures To Advance PAH Candidate Into First Clinical Trial 3/3/2015
Islet Sciences Enters Into Exclusive License Agreement For Phase 2 SGLT2 Inhibitor Remogliflozin Etabonate 3/3/2015
DURECT Corporation (DRRX) Announces Epigenomic Regulator Program Including A New NAFLD/NASH And Acute Organ Injury Product Candidate In Development 3/3/2015
MyoKardia Announces Initiation Of Phase 1 Clinical Study Of MYK-461 For Hypertrophic Cardiomyopathy 3/3/2015
Cerulean Pharma Inc. (CERU) Establishes Clinical Collaboration With The GOG Foundation To Study CRLX101 In Combination With Weekly Paclitaxel In Relapsed Ovarian Cancer 3/3/2015
Epizyme (EPZM) Announces Presentation Of Data From Phase 1 Study Of EZH2 Inhibitor EPZ-6438 (E7438) 3/3/2015
Boehringer Ingelheim Puts Hold on Key Alzheimer's Drug Trial 3/2/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Cancer Of The Fallopian Tube 3/2/2015
TRACON Pharmaceuticals, Inc. (TCON) Announces Positive Phase 1b Results For TRC105 In Combination With Inlyta (Axitinib) At The ASCO 2015 Genitourinary Cancers Symposium 3/2/2015
Almac Discovery Initiates Phase 1 Study Of ALM201 For The Treatment Of Patients With Advanced Ovarian Cancer And Other Solid Tumours 3/2/2015
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc. (VTAE) Release: BACE Inhibitor BI 1181181 Voluntarily Put On Temporary Clinical Hold For Safety Evaluation 2/27/2015
INSYS Therapeutics Announces Its Pharmaceutical Cannabidiol Received Fast Track Designation From FDA For The Treatment Of Dravet Syndrome 2/27/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
Sangamo BioSciences (SGMO) Presents New Clinical Data At CROI 2015 From Trial Of ZFP Therapeutic Designed To Provide Functional Control Of HIV 2/26/2015
ObsEva Reports Positive Phase 1 Results For The First Orally Active Oxytocin Antagonist OBE001 To Treat Preterm Labour 2/26/2015
Innocrin Pharmaceuticals Inc. To Present Interim Results From Its Phase 1/2 Prostate Cancer Clinical Study And Preclinical Results That Demonstrate VT-464 Efficacy In A Clinically-Relevant Enzalutamide-Resistant Mouse Model 2/26/2015
Ampio Pharmaceuticals, Inc. (AMPE) Announces Top-Line Results Of The Double-Blind Multiple Intra-Articular Injections (STRUT) Study Of Ampion In Patients With Moderate To Severe Osteoarthritis Of The Knee 2/25/2015
Anavex (AVXL) Release: ANAVEX 2-73 Could Prevent Alzheimer's Disease In Addition To Modifying And Treating Symptoms 2/25/2015
Cell MedX Corp. (CMXC) Announces Results Of Preliminary Analysis Of Metabolomic Assays In Phase 1 Pilot Clinical Trial 2/25/2015
Adamis Pharmaceuticals (ADMP) Announces Positive Pharmacokinetic Study Results For Its Beclomethasone Dipropionate HFA Product 2/24/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions In Prekallikrein Levels 2/24/2015
Bavarian Nordic (BAVA.CO) Announces Updated Overall Survival Data From Combination Immunotherapy Data Of PROSTVAC Plus Ipilimumab At The 2015 Genitourinary Cancers Symposium 2/24/2015
BioTime (BTX) Announces First Patient Treated In Pivotal Clinical Trial Of Renevia™ For HIV-Associated Lipoatrophy 2/24/2015
Enanta Pharmaceuticals, Inc. Announces JAMA Publication Of Results From AbbVie (ABBV)’s Study Of VIEKIRA PAK™ (Ombitasvir, Paritaprevir, Ritonavir Tablets; Dasabuvir Tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) 2/23/2015
Arrowhead Research Corporation (ARWR) Begins Phase 1 Trial Of ARC-AAT For Treatment Of Liver Disease Associated With Alpha-1 Antitrypsin Deficiency 2/23/2015
ReveraGen BioPharma Announces Start Of Phase 1 Clinical Trial Of VBP15 Dissociative Steroid Drug 2/18/2015
Dipexium Pharmaceuticals (DPRX) Announces Successful Completion And Initial Results Of Phase 1 Skin Sensitization Trial Of Locilex 2/17/2015
Helix Biopharma (TSX:HBP) Initiates Enrollment for Eleventh Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 2/17/2015
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Treatment Shows Efficacy And Tolerability In Heavily Treated Chronic Lymphocytic Leukemia Patients Following Allogeneic Stem Cell Transplant 2/17/2015
Stealth Biotherapeutics Initiates A Clinical Study Of Bendavia For The Treatment Of Orphan Mitochondrial Diseases 2/17/2015
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Colorectal Cancer 2/17/2015
Anaheim Clinical Trials (ACT) ‘Slam Dunks’ Enrollment On Another Japanese Bridging Study 2/16/2015
Galapagos NV (GLPG.BR) Reports Positive Phase 1 Results For GLPG1690 2/16/2015
Bexion Pharmaceuticals Receives Orphan Drug Designation For Saposin C, The Active Ingredient In BXQ-350 For Glioblastoma Multiforme From FDA 2/16/2015
Soligenix (SNGX) Release: Ricin Toxin Vaccine Poster Presented At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC 2/13/2015
Genzyme (GENZ) Presents Data From Its Phase 1b Program For Niemann-Pick Type B At The Lysosomal Disease Network’s WORLD Symposium 2015 2/13/2015
Verastem, Inc. (VSTM) Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma 2/12/2015
Novavax, Inc. (NVAX) Announces Initiation Of Ebola Vaccine Phase 1 Clinical Trial Supported By Non-Human Primate Challenge Data And Documented Rapid Manufacturing Capabilities 2/12/2015
Oncobiologics Inc. Announces ONS-3010 (Humira/Adalimumab Biosimilar) Meets Primary Endpoints In First Clinical Study 2/12/2015
Aileron Therapeutics Initiates Phase 1 Cancer Study Of ALRN-6924 In Advanced Hematologic And Solid Malignancies With Wild Type P53 2/12/2015
BIOCEO15: BioLineRx Ltd. CEO Touts New Celiac Drug, Fleshes Out Novartis AG (NVS) Partnership Terms 2/11/2015
ChromaDex, Inc.'s NIAGEN Nicotinamide Riboside Meets Primary Endpoint In First Human Clinical Study 2/11/2015
Immune Design Corporation (IMDZ) Announces First Patients Dosed In Phase 1 Clinical Trial Of G100 Investigational Immuno-Oncology Agent 2/11/2015
Ultragenyx Pharmaceuticals (RARE) Announces Positive 36-Week Data From Phase 1/2 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis 7 2/11/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Ovarian Cancer 2/11/2015
Edge Therapeutics Reports Initial Data From Its Phase 1/2 NEWTON Trial For EG-1962 For Improvement Of Outcomes After Ruptured Brain Aneurysm 2/11/2015
Heron Therapeutics, Inc. (APPA) Initiates Phase 1 Clinical Study Of HTX-011 For The Treatment Of Post-Operative Pain 2/11/2015
Theravance Biopharma Initiates Patient Registry Study For VIBATIV(R) (telavancin) 2/11/2015
BIOCEO15: ContraFect (CFRXU) CEO Says Lysin, AB Anti-Infectives Are “Game-Changers” in 2015 2/10/2015
Synthetic Biologics, Inc. (SYN) Announces Positive Topline Results From Phase 1b Trial Of SYN-004 To Protect The Microbiome And Prevent C. Difficile Infection 2/10/2015
Apellis Pharmaceuticals Enters Clinical Testing Phase In Its Age-Related Macular Degeneration Program 2/10/2015
Strategic Science & Technologies Initiates Phase 1 Study To Evaluate Topical Sildenafil In Women With Female Sexual Arousal Disorder 2/9/2015
Alkermes plc (ALKS) Announces Positive Topline Results From Phase 1 Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 2/9/2015
Trevena, Inc. (TRVN) Announces Positive Results From Phase 1 Multiple Ascending Dose Study Of TRV734 For Moderate To Severe Acute And Chronic Pain 2/9/2015
Safety And Preliminary Efficacy Of Human Neural Stem Cells In StemCells (STEM)'s Dry AMD Study To Be Presented At Ophthalmology Conference 2/5/2015
Ignyta (RXDX) Receives Orphan Drug Designation From FDA For Entrectinib For The Treatment Of Molecularly Defined Subsets Of Non-Small Cell Lung Cancer 2/5/2015
THERAVECTYS Obtains Orphan Drug Designation From European Medicines Agency For Its Lentiviral Vector-Based Therapeutic Vaccine Against Adult T-Cell Leukemia And Lymphoma 2/5/2015
Proteostasis Therapeutics, Inc. Announces A New Class Of Agents For Cystic Fibrosis Called CFTR Amplifiers And Selects PTI130 As A Development Candidate 2/5/2015
Akaal Pharma Announces Positive Results From Phase 1 Clinical Study Of Novel Topical AKP-11 For The Treatment Of Psoriasis 2/5/2015
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus FOLFOX In Advanced Gastrointestinal Malignancies 2/3/2015
bluebird bio (BLUE)'s Rare Blood Disorder Drug Tagged a Breakthrough by the FDA 2/3/2015
bluebird bio (BLUE) Release: FDA Grants Breakthrough Therapy Designation To Lentiglobin For Treatment Of Beta-Thalassemia Major 2/2/2015
Pluristem Therapeutics (PSTI) Announces Significant New Finding From Its Phase I/II Muscle Injury Trial And Excellent Safety Profile For PLX-PAD Cells At Twelve Months 2/2/2015
Protalix Biotherapeutics, Inc. (PLX) Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease 2/2/2015
Bionomics Limited (BNO.AX) Begins Phase 1b Study With Anxiety Drug Bnc210 2/2/2015
Kamada Ltd. (KMDA) Reports Encouraging Interim Data From Its Phase 1/2 Extension Study: AAT In Pediatric Patients With Type 1 Diabetes 2/2/2015
Alnylam Pharmaceuticals (ALNY) Initiates Phase 1/2 Clinical Trial For ALN-CC5, A Subcutaneously Administered Rnai Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases 2/2/2015
Rock Creek Pharmaceuticals Receives Clinical Trial Application Approval 1/30/2015
First Trial Finds GlaxoSmithKline (GSK) Ebola Shot Safe 1/29/2015
XencorReports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction Of Serum Ige In Healthy Volunteers 1/29/2015
Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity In Rheumatoid Arthritis 1/29/2015
Celldex Therapeutics, Inc. (CLDX) And Bristol-Myers Squibb Company (BMY) Announce Initiation Of Phase 1/2 Combination Study Of Varlilumab And Opdivo® In Advanced Refractory Solid Tumors 1/29/2015
Cleveland Biolabs Inc. (CBLI) Announces Oncology Clinical Development Update For Entolimod 1/29/2015
International Stem Cell Corporation To Conduct Parkinson's Disease Clinical Study In Australia 1/29/2015
Endexx Announces Positive Results Of Initial Diabetic Neuropathy Patient Study 1/29/2015
aTyr Pharma Inc. Announces First FSHD Patient Study Of Resolaris™ 1/28/2015
RestorGenex Granted Orphan Drug Designation For RES-529 For Treatment Of Glioblastoma Multiforme 1/28/2015
Sorrento Therapeutics, Inc. Announces Completion Of Enrollment In The Cynviloq™ Registrational TRIBECA™ Study 1/28/2015
Synageva BioPharma (GEVA) Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted 1/26/2015
Pharmacyte Biotech's Expanded Follow-Up Study On Malignant Ascites Fluid Accumulation In Final Stages Of Preparation 1/26/2015
Cellceutix (CTIX) Plans Clinical Trial In Patients With Ulcerative Proctitis 1/26/2015
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015
Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 1/23/2015
Minerva Neurosciences, Inc. (NERV) Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist For Treatment Of Sleep Disorders Including Primary And Comorbid Insomnia 1/22/2015
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence First-In-Human Clinical Trials Of ADXS-HER2 1/22/2015
Disneyland Measles Outbreak Casts Shadow on Anti-Vaccination Movement 1/21/2015
Tekmira (TKMR) Initiates Phase I Clinical Trial Of TKM-HBV 1/21/2015
Adocia Initiates A Clinical Study On The Post-Meal Effect Of Ultra-Rapid Biochaperone Lispro Insulin Formulation 1/21/2015
Kinex Pharmaceuticals Announces First Patient Dosed With KX2-391 Ointment For Actinic Keratosis In A Phase 1 Clinical Study 1/20/2015
Tobira Therapeutics Inc. Doses First Subject In Phase 1 Clinical Trial Of Cenicriviroc And Pioglitazone 1/20/2015
Spark Therapeutics Initiates Phase 1/2 Clinical Trial Of SPK-CHM For Choroideremia, Expanding Its Pipeline Of Potential Treatments For Rare, Blinding Conditions 1/20/2015
Immunomedics, Inc. (IMMU) Reports Phase 1/2 Results With Sacituzumab Govitecan (IMMU-132) In Patients With Metastatic Gastrointestinal Cancers 1/20/2015
Kite Pharma, Inc. (KITE) Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process 1/20/2015
Verastem, Inc. (VSTM) Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma 1/20/2015
Cellceutix (CTIX) Reports Spleen Lesion "Disappears" In Patient With Metastatic Stage 4 Ovarian Cancer In Clinical Trial Of Anti-Cancer Drug Kevetrin 1/20/2015
Neurocrine Biosciences, Inc. (NBIX) Announces Granting Of Orphan Drug Status For NBI-77860 In Congenital Adrenal Hyperplasia 1/19/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
OncoMed Pharmaceuticals, Inc. (OMED) Presents Final Phase 1b Safety, Efficacy And Biomarker Data For Tarextumab In Pancreatic Cancer At The 2015 Gastrointestinal Cancer Symposium 1/19/2015
J.P. Morgan: Five Prime Therapeutics, Inc. (FPRX) CEO Says Experimental Drug to Head Into Six New Tumor Trials Via Bristol-Myers Squibb Company (BMY) 1/16/2015
J.P. Morgan: Juno Therapeutics (JUNO) Touts 10 New Drugs for Six Diseases, Loves New CAR-T Platform 1/16/2015
Antibe Therapeutics Inc. (ATE.V) Suspends Its Phase I Clinical Trial Due To Safety Concerns 1/16/2015
Pfizer (PFE)'s Working on Once-a-Year Anti-Cholesterol Shot 1/15/2015
Auspex Pharmaceuticals (ASPX) Receives FDA Orphan Drug Designation Of SD-809 For Treatment Of Tourette Syndrome In The Pediatric Population 1/15/2015
OncoMed Pharmaceuticals, Inc. (OMED) Enrolls First Biomarker-Selected Patient In Expansion Stage Of Anti-Notch1 Phase 1a Trial In Solid Tumors 1/15/2015
Novan Therapeutics To Present Successful Clinical Study Results Of Lead Product Candidate SB204 For The Treatment Of Acne Vulgaris 1/15/2015
Newron Pharmaceuticals (NWRN) Announces Results Of Phase I Study Of NW-3509 Phase II Study In Schizophrenia Patients Planned For Q2 2015 1/15/2015
Aptose Biosciences Doses First Patient In Phase 1b Clinical Study Of APTO-253 In Relapsed Or Refractory Hematological Malignancies 1/14/2015
Ascendis Pharma A/S Announces Initiation Of A Phase 1 Single Ascending Dose Study Of Transcon Treprostinil 1/14/2015
Sarepta (SRPT) Announces First Patient Dosed In European Phase1/2 Study Of SRP-4053 In Duchenne Muscular Dystrophy Patients 1/14/2015
BioLine Announces Completion Of Enrollment In CE Mark Registration Trial Of BCM (BL-1040), A Novel Medical Device For Prevention Of Cardiac Remodeling Following Acute Myocardial Infarction 1/14/2015
BioMarin (BMRN) Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study Of BMN 190 For Treatment Of CLN2 Disorder, A Form Of Batten Disease 1/13/2015
Relmada Therapeutics Reaches Midway Point In Dose Escalation For Phase One Study Of Novel NMDA Receptor Antagonist D-Methadone 1/13/2015



//-->